Gemcitabine HCl

Suppliers

Names

[ Name ]:
Gemcitabine HCl

[Synonym ]:
dFdC,Gemzar,Lilly)
MFCD01735988
dFdC Gemzar (Lilly) LY-188011 dFdC dFdCyd
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one hydrochloride
Gemcitabine hydrochloride
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-2(1H)-pyrimidinone hydrochloride
Cytidine, 2'-deoxy-2',2'-difluoro-, hydrochloride (1:1)
2'-Deoxy-2',2'-difluorocytidine hydrochloride (1:1)
Gemcitabine HCl
Gemcitabine HCl(TABINES)
Gemcitabine (Hydrochloride)

Chemical & Physical Properties

[ Boiling Point ]:
482.7ºC at 760 mmHg

[ Melting Point ]:
>250°C dec.

[ Molecular Formula ]:
C₉H₁₂ClF₂N₃O₄

[ Molecular Weight ]:
299.659

[ Exact Mass ]:
299.048431

[ PSA ]:
110.60000

[ LogP ]:
0.09460

[ Vapour Pressure ]:
2.41E-11mmHg at 25°C

[ Storage condition ]:
Desiccate at +4°C

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: HA3840000

CHEMICAL NAME :: Cytidine, 2'-deoxy-2',2'-difluoro-, monohydrochloride

CAS REGISTRY NUMBER :: 122111-03-9

LAST UPDATED :: 199706

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: C9-H11-F2-N3-O4.Cl-H

MOLECULAR WEIGHT :: 299.69

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 15 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - parturition Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

REFERENCE :: TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 48,365,1993

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 15 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

REFERENCE :: TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 48,365,1993

Safety Information

[ Symbol ]:

GHS08

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H360

[ Precautionary Statements ]:
P201-P280-P308 + P313

[ Hazard Codes ]:
Xi: Irritant;

[ Risk Phrases ]:
R21

[ Safety Phrases ]:
25-26-36/37-53

[ RIDADR ]:
NONH for all modes of transport

[ HS Code ]:
2934999090

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2934999090

[ Summary ]:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles

Quantitative proteomics of the yeast Hsp70/Hsp90 interactomes during DNA damage reveal chaperone-dependent regulation of ribonucleotide reductase.

J. Proteomics 112 , 285-300, (2015)

The highly conserved molecular chaperones Hsp90 and Hsp70 are indispensible for folding and maturation of a significant fraction of the proteome, including many proteins involved in signal transductio...

Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer.

Biomaterials 53 , 763-74, (2015)

Multi-drug delivery focuses on different signaling pathways in cancer cells that have synergistic anti-proliferative effects. In this study, we developed multi-prodrug nanocarriers (MPDNCs) consisting...

Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer.

Clin. Cancer Res. 20(24) , 6406-17, (2014)

This study characterized the therapeutic efficacy of a systemically administered formulation of 3-bromopyruvate (3-BrPA), microencapsulated in a complex with β-cyclodextrin (β-CD), using an orthotopic...